Advertisement
Advertisement
CVKD
Cadrenal Therapeutics, Inc. Common Stock
1.94
USDSponsored
-0.01
-0.51%
Aug 10, 15:58 UTC -4
Closed
After-Market
1.96
+0.02
+1.08%
CVKD Earnings Reports
Positive Surprise Ratio
CVKD beat 3 of 10 last estimates.
30%
Next Report
Today
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.44
Implied change from Q1 26 (Revenue/ EPS)
--
/+38.46%
Implied change from Q2 25 (Revenue/ EPS)
--
/-22.99%
Cadrenal Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, CVKD reported earnings of -1.04 USD per share (EPS) for Q1 26, beating the estimate of -1.65 USD, resulting in a 37.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.43% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -1.44 USD, with revenue projected to reach -- USD, implying an increase of 38.46% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Cadrenal Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Cadrenal Therapeutics, Inc. Common Stock reported EPS of -$1.04, beating estimates by 37.06%, and revenue of $0.00, 0% as expectations.
How did the market react to Cadrenal Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.43%, changed from $6.17 before the earnings release to $6.02 the day after.
When is Cadrenal Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Cadrenal Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Cadrenal Therapeutics, Inc. Common Stock is expected to report EPS of -$1.44 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement